Evacetrapib at a Supratherapeutic Steady State Concentration Does Not Prolong QT in a Thorough QT/QTc Study in Healthy Participants

Conclusions:
Evacetrapib is not associated with QT interval prolongation, even at supratherapeutic doses.

Source: Journal of Cardiovascular Pharmacology and Therapeutics - April 16, 2014 Category: Cardiology Authors: Suico, J. G., Friedrich, S., Krueger, K. A., Zhang, W. Tags: Clinical Studies Source Type: research